Ulcerative colitis (UC) is an inflammatory bowel disease. It causes irritation, inflammation, and ulcers in the lining of the large intestine.
Investigators
Open Research Studies for Ulcerative Colitis
ABIVAX ABTECT
Enrolling: Yes
Principle Investigator: Monika Fischer
Duration: 56 weeks, 6 total visits.
Patient Population: Adult patients with Ulcerative Colitis.
Interested in this study? Please contact the IBD research team: iuibd@iu.edu
SPARC IBD
Enrolling: Yes
Principle Investigator: Satya Kurada, MD
Duration: All bio-specimen collections and chart reviews will continue until 2026
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Intervention: Medical chart reviews and biological specimen collection.
Interested in this study? Please contact the IBD research team: iuibd@iu.edu
Closed Ulcerative Colitis Studies
Duration: One time scan (1 in person visit)
Patient Population: Adult patients with Crohn's Disease or Ulcerative Colitis fasting for 2 hours prior.
Duration: Indefinite or upon withdraw
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Procedures: Patient surveys before every office visit & medical chart reviews
Duration: 5 years (visits every 4 weeks)
Patient Population: Adult patients with moderate to severe UC with failure to at least 1 approved therapy.
Drug(s): Guselkumab, Golimumab, or the co-formulation (9% change of placebo)
Duration: 12 months
Patient Population: Any patient with Ulcerative Colitis starting Tofacitinib (Xeljanz) for the first time as part of their standard treatment for UC.
Study Intervention: Medical chart review and e-mail patient questionnaires (Enrollment and participation is done via phone.)